Across TCGA pan-cancer cohorts, TOGARAM1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TOGARAM1 data layer compared with 24 for mass-spec protein and 13 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TOGARAM1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TOGARAM1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where TOGARAM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.270	0.820	.013	37	view →
HNSC	OS	Median	II,III,IV	0.749	0.947	.019	7	view →
LUAD	DFS	Median	II,III,IV	0.748	0.200	.017	7	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TOGARAM1 tumor-vs-normal RNA expression · all TOGARAM1 data types